Karyopharm Therapeutics
KPTI
77 hedge funds and large institutions have $316M invested in Karyopharm Therapeutics in 2017 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 37 increasing their positions, 14 reducing their positions, and 4 closing their positions.
958% more call options, than puts
Call options by funds: $1.3M | Put options by funds: $123K
164% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 14
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
26% more capital invested
Capital invested by funds: $251M → $316M (+$64.2M)
5% more funds holding
Funds holding: 73 → 77 (+4)
0.13% more ownership
Funds ownership: 3.93% → 4.06% (+0.13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$2.59M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$2.15M |
| 3 |
Millennium Management
New York
|
+$1.45M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.42M |
| 5 |
IHM
Iguana Healthcare Management
New York
|
+$955K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.03M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$716K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$393K |
| 4 |
Barclays
London,
United Kingdom
|
-$281K |
| 5 |
TI
Trexquant Investment
Stamford,
Connecticut
|
-$202K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IA
76
IFP Advisors
Tampa,
Florida
| $2K | – | – | – |
|
|
TI
77
Trexquant Investment
Stamford,
Connecticut
| – | -$202K | -1,490 | Closed |
|
|
PPA
78
Parametric Portfolio Associates
Seattle,
Washington
| – | -$177K | -1,306 | Closed |
|
79
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$148K | -1,088 | Closed |
|
80
Creative Planning
Overland Park,
Kansas
| – | -$45K | -333 | Closed |
|
|
CG
81
Cutler Group
San Francisco,
California
| – | -$23.8K | -166 | -99% |
|
KPTI Hedge Fund Activity: Q3 2017 in Review
77 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q3 2017, worth a combined $316M — up 26% from $251M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new KPTI positions and 4 closed out — a net gain of 4 holders — while 37 added to existing stakes and 14 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $2.59M. The largest seller was Fidelity Investments, cutting an estimated $3.03M.
- 77 institutional investors held Karyopharm Therapeutics (KPTI) as of Q3 2017, up from 73 in Q2 2017.
- Funds reported $316M of Karyopharm Therapeutics stock for Q3 2017, up 26% quarter-over-quarter.
- 8 funds opened new Karyopharm Therapeutics positions in Q3 2017 and 4 closed out, a net change of +4 holders.
- The largest Karyopharm Therapeutics buyer in Q3 2017 was JP Morgan Chase, an estimated $2.59M added.
- The largest Karyopharm Therapeutics seller in Q3 2017 was Fidelity Investments, an estimated $3.03M sold.
Based on aggregated 13F filings for Q3 2017.